{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:35:01Z","timestamp":1787578501005,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Whether nebulized polymyxin B should be used as an adjunctive therapy or substitution strategy to intravenous polymyxin B for the treatment of ventilator-associated pneumonia (VAP) remains controversial. This study\u2019s aim is to evaluate the efficacy and safety of different administration ways of polymyxin B in the treatment of ventilator-associated pneumonia caused by extensively drug-resistant Gram-negative bacteria(XDR-GNB).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This retrospective cohort study enrolled ventilator-associated pneumonia patients caused by XDR-GNB treated with polymyxin B in the intensive care unit. Patients were categorized by the administration methods as intravenous (IV) group, inhaled (IH) group, and the intravenous combined with inhaled (IV + IH) group. Microbiological outcome and clinical outcome were compared in each group. The side effects were also explored.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 111 patients were enrolled and there was no difference in demographic and clinical characteristics among the three groups. In terms of efficacy, clinical cure or improvement was achieved in 21 patients (55.3%) in the intravenous group, 19 patients (50%) in the IH group, and 20 patients (57.1%) in IV + IH group (<jats:italic>p<\/jats:italic> = 0.815). All three groups showed high success rates in microbiological eradication, as 29 patients with negative cultures after medication in inhaled group. Among all the patients who had negative bacterial cultures after polymyxin B, the inhaled group had significantly shorter clearance time than the intravenous group (<jats:italic>p<\/jats:italic> = 0.002), but with no significant difference in 28-day mortality. Compared with intravenous group, a trend towards a lower risk of acute kidney injury was observed in inhaled group (<jats:italic>p<\/jats:italic> = 0.025).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> From the perspective of minimal systemic renal toxicity, nebulized polymyxin B as a substitution strategy to intravenous polymyxin B for the treatment of ventilator-associated pneumonia caused by XDR-GNB is feasible.<\/jats:p>","DOI":"10.3389\/fphar.2023.1222044","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:57:06Z","timestamp":1693551426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Rupeng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1517\/17425247.2012.660480","article-title":"Inhaled colistin for lower respiratory tract infections","volume":"9","author":"Antoniu","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11908-015-0494-5","article-title":"Ventilator-associated pneumonia (VAP) with multidrug-resistant (MDR) pathogens: optimal treatment?","volume":"17","author":"Bailey","year":"2015","journal-title":"Curr. Infect. Dis. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J. Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1164\/rccm.201308-1499LE","article-title":"Heterogeneity in the definition of mechanical ventilation duration and ventilator-free days","volume":"189","author":"Contentin","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Dm","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/QCO.0000000000000633","article-title":"Optimizing aerosol delivery of antibiotics in ventilated patients","volume":"33","author":"Ehrmann","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit. Care Lond. Engl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial susceptibility of acinetobacter calcoaceticus-acinetobacter baumannii Complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance Program (1997-2016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","article-title":"Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli: a Chinese consensus statement","volume":"22","author":"Guan","year":"2016","journal-title":"Clin. Microbiol. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jgar.2016.12.016","article-title":"Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients","volume":"9","author":"Gupta","year":"2017","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin. Infect. Dis. Soc. Am."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1093\/cid\/ciy657","article-title":"Current status and trends of antibacterial resistance in China","volume":"67","author":"Hu","year":"2018","journal-title":"Clin. Infect. Dis. Soc. Am."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit. Care Lond. Engl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1086\/657242","article-title":"Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"51","author":"Kofteridis","year":"2010","journal-title":"Clin. Infect. Dis. Soc. Am."},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","article-title":"Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy","volume":"65","author":"Kubin","year":"2012","journal-title":"J. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jac\/dkx409","article-title":"Pharmacokinetics\/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models","volume":"73","author":"Landersdorfer","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13613-022-01033-5","article-title":"Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study","volume":"12","author":"Liu","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00134-010-1879-4","article-title":"Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa","volume":"36","author":"Lu","year":"2010","journal-title":"Intensive Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0954-6111(94)90028-0","article-title":"Nebulized colistin causes chest tightness in adults with cystic fibrosis","volume":"88","author":"Maddison","year":"1994","journal-title":"Respir. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jcrc.2017.11.022","article-title":"Chronic kidney disease after acute kidney injury associated with intravenous colistin use in survivors of severe infections: a comparative cohort study","volume":"44","author":"Meraz-Mu\u00f1oz","year":"2018","journal-title":"J. Crit. Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1164\/rccm.200210-1167OC","article-title":"Aerosol delivery and modern mechanical ventilation: in vitro\/in vivo evaluation","volume":"168","author":"Miller","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin. Infect. Dis. Soc. Am."},{"key":"B31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","article-title":"A review on colistin nephrotoxicity","volume":"71","author":"Ordooei Javan","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1164\/rccm.201312-2161OC","article-title":"Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit","volume":"189","author":"Palmer","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: a narrative review","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/antibiotics8020038","article-title":"Polymyxins: to combine or not to combine?","volume":"8","author":"Perez","year":"2019","journal-title":"Antibiot. Basel Switz."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/jac\/dki461","article-title":"Pharmacokinetics of inhaled colistin in patients with cystic fibrosis","volume":"57","author":"Ratjen","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/cc6877","article-title":"Diagnosis of ventilator-associated pneumonia: a systematic review of the literature","volume":"12","author":"Rea-Neto","year":"2008","journal-title":"Crit. Care Lond. Engl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European society of clinical Microbiology and infectious diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cmi.2015.12.016","article-title":"Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines","volume":"22","author":"Sol\u00e9-Lleonart","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase\u2013producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of clinical pharmacy (ACCP), European society of clinical Microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective Pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijantimicag.2013.12.002","article-title":"Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium","volume":"43","author":"Tuon","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijantimicag.2017.12.020","article-title":"Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcf.2003.12.005","article-title":"Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study","volume":"3","author":"Westerman","year":"2004","journal-title":"J. Cyst. Fibros. Soc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2016.08.010","article-title":"Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation","volume":"48","author":"Zavascki","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"018822","DOI":"10.1128\/AAC.01882-17","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network","volume":"62","author":"Zhang","year":"2018","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1222044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:57:10Z","timestamp":1693551430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1222044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1222044"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1222044","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"1222044"}}